...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sao Paulo Medical Journal >The role of HER2eu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma
【24h】

The role of HER2eu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma

机译：HER2 / neu，BCL2，p53基因和增殖细胞核蛋白在局部前列腺癌中作为分子预后指标的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT: Prostate cancer is the most frequent solid genitourinary neoplasm in men. Involvement of several genes has been described in the promotion and progression of prostate carcinoma. OBJECTIVE: To study the expression of the oncogenes HER2eu and BCL2, tumor suppressor gene p53 and the tumor proliferation rate in 150 radical prostatectomy specimens, in order to define their role as prognostic parameters in localized prostate cancer. TYPE OF STUDY: Prospective study. SETTING: Universidade Federal de S?o Paulo and Hospital Sírio Libanês, Sao Paulo PARTICIPANTS: One hundred and fifty men who were submitted to radical prostatectomy between August 1997 and August 1998, for localized prostate cancer. MAIN MEASUREMENTS: All specimens underwent evaluation in their entirety, to determine tumor volume percentage, tumor extent and Gleason score. Immunohistochemistry was performed to determine gene expression using anti- HER2eu, BCL2 and p53 antibodies, and proliferating cell nuclear antigen. The chi-squared test was used for correlation between gene expression, proliferative activity and histological variables. RESULTS: Thirty percent of the cases were p53 positive. There was positive correlation between p53 expression and tumor stage. The p53 expression was 22.9% and 42.6% for pT2 and pT3 tumors, respectively (p = 0.01). Expression of HER2eu, BCL2 and proliferating cell nuclear antigen was identified in 66%, 23% and 43% of patients, respectively. There was no correlation between these three parameters and tumor volume, Gleason score or tumor stage. CONCLUSION: One-third of prostate adenocarcinomas express p53 protein, and this characteristic is related to tumor stage. HER2eu is frequently expressed in prostate carcinomas, with no correlation with histological parameters. BCL2 is rarely expressed, and together with proliferative activity has no relationship with prognostic pathological variables in these neoplasms.
机译：背景：前列腺癌是男性中最常见的实体泌尿生殖道肿瘤。在前列腺癌的促进和发展中已经描述了几种基因的参与。目的：研究150例前列腺癌根治术标本中癌基因HER2 / neu和BCL2的表达，抑癌基因p53的表达以及肿瘤的增殖率，以明确其在局部前列腺癌预后中的作用。研究类型：前瞻性研究。地点：圣保罗联邦大学和圣保罗里瓦内斯医院，圣保罗参与者：1997年8月至1998年8月间，有150名因局部前列腺癌而接受根治性前列腺切除术的男性。主要测量：所有标本均进行整体评估，以确定肿瘤体积百分比，肿瘤程度和格里森评分。使用抗HER2 / neu，BCL2和p53抗体以及增殖细胞核抗原进行了免疫组织化学以确定基因表达。卡方检验用于基因表达，增殖活性和组织学变量之间的相关性。结果：30％的病例为p53阳性。 p53表达与肿瘤分期呈正相关。 pT2和pT3肿瘤的p53表达分别为22.9％和42.6％（p = 0.01）。分别在66％，23％和43％的患者中鉴定出HER2 / neu，BCL2和增殖性细胞核抗原的表达。这三个参数与肿瘤体积，格里森评分或肿瘤分期之间没有相关性。结论：三分之一的前列腺腺癌表达p53蛋白，这一特征与肿瘤的分期有关。 HER2 / neu常在前列腺癌中表达，与组织学参数无关。 BCL2很少表达，并且其增殖活性与这些肿瘤的预后病理变量无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号